EB-1010: The even-next generation antidepressant gets a name

The even-next generation antidepressant is navigating its way through clinical trials. Like any newborn, it’s been given a name. EB-1010 is now amitifadine.

But don’t get too excited – yet. You won’t see it for a while, unless you sign-up for the clinical trial. I’ll tell you how you can do that in a short.

Update: Effective September 2017, the development of amitifadine for the treatment of major depressive disorder has been discontinued. However, it continues to be under development for the treatment of alcoholism and smoking withdrawal.

Amitifadine (was EB-1010)

I began writing about what’s now known as amitifadine this past March. In fact, I’ve written two pieces. Check ’em out…

Future Psych Meds: The TRIs
Depression Research: A triple reuptake inhibitor

Developed by Euthymics Bioscience, amitifadine has been designed to treat major depressive disorder (MDD). It’s a triple reuptake inhibitor that largely manipulates the neurotransmitter serotonin. Half as much of its action is aimed at norepinephrine – and one-eighth as much at dopamine.

The idea was to approximate the two product combinations found to have favorable outcomes in the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study. Not familiar with it? Here’s a great place to start.

According to Euthymics…

“By overlaying norepinephrine and dopamine on the well-established role of serotonin it is believed that amitifadine has the potential to increase antidepressant efficacy while reducing the adverse effects that can limit compliance with medication including weight gain, sexual dysfunction and impaired cognition.”

The Trials

Amitifadine fared very well in its phase 2 clinical trial. Of note was its impact upon anhedonia (loss of interest in what were pleasurable activities).

It showed an excellent safety profile. And there was no evidence of weight gain or loss of sexual function.

Its phase 2b/3a clinical trial, known as TRIADE ( Triple Reuptake Inhibitor Anti-Depressant Effects), began this past March. It compares amitifadine, paroxetine (Paxil), and placebo in participants who’ve had no luck with one course of an SSRI (Paxil, Zoloft, Prozac, Celexa, etc.) or SNRI (Cymbalta, Effexor).

If you’re interested in participating, the actual study name is…

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Here’s a link with all sorts of info to get you started.

Initial results are expected in the summer of 2012.

The Close

Just as I did with Viibryd, I’ll keep you posted on the development of amitifadine. Sure, its presence on pharmacy shelves is a good bit off.

But it’s information you need to know, especially if you’re interested in participating in the clinical trial.

For a listing of all chipur articles on meds and supplements for the mood and anxiety disorders, click away here.